• Promimic posted Q2 2026 net sales of SEK 12 million, up 6% from a year earlier.
• Operating loss widened to SEK 1.4 million; net loss was unchanged at SEK 1.5 million, with EPS at SEK -0.08.
• Cash flow for the period improved to SEK -2.3 million; cash and cash equivalents fell to SEK 19.8 million.
• FDA cleared an implant using its nanostructured zirconium phosphate ceramic surface, positioned as a predicate device for customer approvals.
• Management cited stronger underlying demand in implant-related revenue, while noting currency headwinds and cost control efforts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Promimic AB published the original content used to generate this news brief via Cision (Ref. ID: 202608200130BITN____UKPR__SV_20260813-BIT-7571-0) on August 20, 2026, and is solely responsible for the information contained therein.